Pain due to multiple sclerosis: Analysis of the prevalence and economic burden in Canada

Pain Research and Management

Volumn 12, Issue 4, 2007, Pages 259-265

  Piwko, Charles ^a   Desjardins, Olivier B ^a   Bereza, Basil G ^a   Machado, Marcio ^a,b   Jaszewski, Barbara ^c   Freedman, Mark S ^d   Einarson, Thomas R ^a,e   Iskedjian, Michael ^a  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b UNIVERSITY OF CHILE   (Chile)

^c Medical and Scientific Affairs   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Burden of illness; Multiple sclerosis; Pain; Patient reported outcomes; Prevalence

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BACLOFEN; CANNABIS; CARBAMAZEPINE; GABAPENTIN; IBUPROFEN; NAPROXEN; OPIATE; OXYBUTYNIN; PARACETAMOL; SPASMOLYTIC AGENT; TIZANIDINE;

ACUPUNCTURE; ADULT; ARTICLE; CANADA; CHIROPRACTIC; CORRELATION COEFFICIENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MASSAGE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PREVALENCE; RESOURCE MANAGEMENT; SELF REPORT; TREATMENT RESPONSE; YOGA; CLINICAL PRACTICE; DISABILITY; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; HEALTH SERVICE; HEALTH SURVEY; MIDDLE AGED; NEUROLOGY; PHYSICIAN; STATISTICS; UTILIZATION REVIEW;

ADULT; ANALGESICS; CANADA; COST OF ILLNESS; DISABILITY EVALUATION; FEMALE; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HEALTH SERVICES; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGY; PAIN; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PREVALENCE;

EID: 39049152409     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/128681     Document Type: Article

References (30)

1. Bruck G, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003;24:S265-7.
2. Multiple Sclerosis Society of Canada. MS Information - Frequently Asked Questions. (Version current at April 13, 2007).
3. Brassington J, March N. Neuropsychological aspects of multiple sclerosis. Neuropsychol Rev 1998;8:43-77.
4. Brichetto G, Messmer Uccelli M, Mancardi G, Solaro C. Symptomatic medication use in multiple sclerosis. Mult Scler 2003;9:458-60.
5. Archibald C, McGrath P, Ritvo P. Pain prevalence, severity and impact in a clinical sample of multiple sclerosis patients. Pain 1994;58:89-93.
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
7. Beck C, Metz L, Svenson L, Patten S. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 2005;11:516-9.
8. Solaro C, Lunardi G, Mancardi G. Pain and MS. Int MS J 2003;10:14-9.
9. Solaro C, Brichetto G, Amato M, et al. The prevalence of pain in multiple sclerosis. Neurology 2004;63:919-21.
10. Burks J. A review of current medical aspects of multiple sclerosis. J Neurol Rehabil 1992;6:131-9.
11. Indaco A, Iachetta C, Nappi C, Socci L, Carrieri P. Chronic and acute pain syndromes in patients with multiple sclerosis. Acta Neurol Scand 1994;16:97.102.
12. Moulin D. Pain in central and peripheral demyelinating disorders. Neurol Clin 1998;16:889-97.
13. Maloni H. Multiple sclerosis and pain. Consortium for multiple sclerosis. (Version current at April 23, 2004).
14. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: A systematic review. Health Technol Assess 2003;7:1-111.
15. Pollman W, Feneberg W, Steinbrecher A, Haupts M, Henze T. Therapy of pain syndromes in multiple sclerosis: An overview with evidence-based recommendations. Fortschr Neurol Psychiatr 2005;73:268-85.
16. The Canadian Burden of Illness Study Group. Burden of Illness of Multiple Sclerosis: Part I: Cost of Illness. Can J Neurol Sci 2006;25:23-30.
17. Grima D, Torrance G, Francis G, Rice C, Rosner A, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6:91-8.
18. Amato M, Battaglia M, Caputo D, et al. The costs of multiple sclerosis: A cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002;249:152-63.
19. Whetten-Goldstein K, Sloan F, Goldstein L, Kulas E. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25.
20. Henriksson F, Fredrikson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35.
21. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002;104:272-5.
22. Grudzinski A, Hakim Z, Cox E, Bootman J. The economics of multiple sclerosis: Distribution of costs and relationship to disease severity. Pharmacoeconomics 1999;15:229-40.
23. Clanet M, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol 2000;13:263-70.
24. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: Health utilities index. Pharmacoeconomics 1995;7:490-502.
25. Aday L. Designing and Constructing Health Surveys. A Comprehensive Guide, San Francisco: Jossey-Bass Publishers, 1996.
26. Cochran W. Sampling Techniques. Wiley Series in Probability and Mathematical Statistics - Applied. New York: John Wiley & Sons, 1977.
27. StatsCan. Statistics Canada. (Version current April 13, 2007).
28. Ehde D, Gibbons L, Chwastiak L, Bombardier C, Sullivan M, Kraft G. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler 2003;9:605-11.
29. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004;62:2098-100.
30. Orlewska E, Mierzejewski P, Zaborski J, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 2005;12:31-9.